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admissions across NSW, of which 815 met inclusion criteria for HFrEF.
Cost estimates were calculated from the Pharmaceutical Benefits Scheme (PBS) data for the cheapest agent within a drug class. The cost of hospital admission for heart failure was estimated using The National Efficient Price (NEP) 2018 calculator issued by the Independent Hospital Pricing Authority (IHPA) in Australia.
Of the 815 patients that met inclusion criteria for hospital admission due to HFrEF, the annual rate of readmission for heart failure was 52%, with all cause mortality rate being 14%. We found a 77% average reduction in mortality benefit and a 71% average increase in rehospitalisation due to suboptimal pharmacotherapy. In our cohort, 28 deaths and 123 rehospitalisations could have been prevented by pharmacotherapy optimisation. The annual cost per patient of optimising pharmacotherapy was $135.35, resulting in a total projected cost of $303387.48 to optimise HFrEF pharmacotherapy across NSW.
The gap in optimal pharmacotherapy prescription for heart failure is a major contributing factor to hospital readmission, thus posing a significant economic burden to the NSW healthcare system. More comprehensive Australiaspecific cost-benefit analyses including recommended device therapies will better elucidate this major public health burden.
http://dx.doi.org/10.1016/j.hlc.2019.06.079
Decline in Left Ventricular Ejection Fraction in Patients Undergoing Pacemaker Implantation
H. Thakkar 1, * , K. Negishi 1,2 , J. Lipton 1 1 Royal Hobart Hospital, Hobart, Australia 2 Menzies Institute of Research, Hobart, Australia Background: RV pacing has been associated with impaired left ventricular function resulting in heart failure. Prediction of patients susceptible to this condition is important as implantation of an LV lead may prevent it.
Aim: The aim of this study was to identify clinical, ECG and echocardiographic predictors of decrease in LV function in patients undergoing pacemaker implantation.
Methods: Retrospective analysis of 106 consecutive patients with preserved LVEF receiving a pacemaker at a tertiary hospital from 2010 to 2018 with follow up echo >6 months post implantation. We stratified the patients into groups based on tercile of LVEF change.
Results: Mean ± SD age was 72.7 ± 12.6 yrs; 34.9% were female; baseline mean LVEF was 58 ± 9%. Pacing indication was sinus node diseases (39%) or AV conduction diseases (61%). After a median (25-75 percentile) follow up of 3 (1-4) yrs, LVEF decreased by 8.4 ± 11.2%, ranging from +20%∼-4% (first tercile), -4∼-12% (second), and -12∼-45% (third).
Patients with greatest LVEF decrease (n = 72; 4-45% drop) were less likely to have atrial fibrillation/flutter pre-implant (49% vs 79%; p = 0.003), had a higher pre-implant LVEF (60% vs 54%; p < 0.05) than patients with LVEF being no change or increase (n = 34).
Pacing indication, baseline QRS width, RV lead position, and pacing burden did not significantly differ between groups.
Conclusion: LVEF reduction occurred in 73.6% of patients undergoing pacemaker implantation for bradycardia; standard clinical, ECG and echo parameters failed to identify this group. Diabetes is associated with an increased risk of heart failure due to altered structure and function of the heart, commonly termed diabetic cardiomyopathy. Mice are the most widely utilised for experimental studies investigating diabetes, however most are genetic models of diabetes (e.g. db/db, ob/ob) and do not reflect the human condition due to their altered leptin signalling. We sought to characterise the altered cardiac, kidney and liver structure and function in a mouse model of T2D-induced cardiomyopathy incorporating low-dose streptozotocin (STZ) and high-fat diet.
Male 6-week-old FVB/N mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) followed by 26 weeks of high-fat diet (42% energy from lipids, SF04-001, Speciality Feeds) to induce T2D. Non-diabetic (ND) mice received vehicle and normal chow diet. Blood glucose (fortnightly), Doppler and tissue Doppler echocardiography, body composition, plasma insulin, markers of myocardial, kidney and liver structure, remodelling and function, were assessed. T2D mice had significantly increased weight and fat mass, exhibited increased blood glucose and plasma insulin, and albuminuria (P < 0.05 for all). Heart weight and left ventricular weight, as well as kidney weight were unaltered with T2D, however liver and spleen weights were significantly increased (P < 0.05). Markers of fibrosis (MMP9, PAI-1), hypertrophy (␤-myosin heavy chain) and apoptosis p-P46 JNK) were increased in T2D hearts (P < 0.05 for all). At endpoint, there was clear evidence of diastolic dysfunction in terms of reduced E/A ratio and e'/a' ratio, and prolonged deceleration time and IVRT (P < 0.05 for all). In the kidney,
